로딩 중…
지수 로딩 중…
Immatics N.V.
IMTX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
DE
DE$9.02+4.16%
2026-08-03
Financials
Valuation Metrics
Immatics N.V.'s Market Cap is $1.23B. At end of 2025 it was $584M. Ranked #2391 of 3,111 in US market (top 77%), #961 of 1,445 on NASDAQ (top 67%), #182 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.23B | US#2,391/3,111 Sec#182/269 |
| Revenue | $42M | US#2,877/3,111 Sec#162/269 |
| Net Income | $-243M | US—/3,111 Sec—/269 |
| Total Assets | $639M | US#2,663/3,111 Sec#136/269 |
| Net Assets | $536M | US#2,205/3,111 Sec#106/269 |
| Value | ||
| P/B | 2.30x | US#1,322/3,111 Sec#62/269 |
| P/S | 29.15x | US#2,851/3,111 Sec#158/269 |
| FCF Yield | -17.34% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -45.36% | US#2,723/3,111 Sec#165/269 |
| ROA | -38.05% | US#2,928/3,111 Sec#187/269 |
| Op. Margin | -570.30% | US#2,905/3,111 Sec#164/269 |
| Revenue Growth | -59.04% | US#2,898/3,111 Sec#165/269 |
| Earnings Growth | -1390.89% | US#2,376/3,111 Sec#94/269 |
| Financial Health | ||
| Debt Ratio | 19.19% | US#217/3,111 Sec#79/269 |
| Total Debt | $18M | US#2,742/3,111 Sec#187/269 |
| FCF | $-214M | US#2,747/3,111 Sec#222/269 |
| Cash | $354M | US#1,308/3,111 Sec#72/269 |
| Current Ratio | 8.78x | US#279/3,111 Sec#93/269 |
| Performance | ||
| 1Y Return | 39.20% | US#1,046/3,111 Sec#140/269 |
| 1M Return | -9.35% | US#2,590/3,111 Sec#198/269 |
| From 52W High | -27.32% | US#2,116/3,111 Sec#162/269 |
| 1Y MDD | -27.80% | US#1,215/3,111 Sec#74/269 |
| Trading | ||
| Volume | 249,086 shares | US#2,648/3,111 Sec#251/269 |
| Trading Value | $2M | US#2,933/3,111 Sec#246/269 |
| Per Share | ||
| EPS | $-1.62 | US—/3,111 Sec—/269 |
| BPS | $4.15 | US#2,306/3,111 Sec#146/269 |